Certara (CERT) – Investment Analysts’ Weekly Ratings Changes

Certara (NASDAQ: CERT) recently received a number of ratings updates from brokerages and research firms:

• 5/29/2026 – Certara had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 5/12/2026 – Certara had its price target lowered by BMO Capital Markets from $7.00 to $6.00. They now have a “market perform” rating on the stock.
• 5/12/2026 – Certara had its price target lowered by Craig Hallum from $10.00 to $8.00. They now have a “hold” rating on the stock.
• 5/12/2026 – Certara had its price target lowered by Stephens from $10.00 to $9.00. They now have an “overweight” rating on the stock.
• 5/12/2026 – Certara had its price target lowered by Barclays PLC from $8.00 to $6.50. They now have an “equal weight” rating on the stock.
• 5/12/2026 – Certara had its price target lowered by Morgan Stanley from $11.00 to $10.00. They now have an “equal weight” rating on the stock.
• 5/12/2026 – Certara had its price target lowered by Robert W. Baird from $7.00 to $6.00. They now have a “neutral” rating on the stock.
• 4/13/2026 – Certara had its price target lowered by KeyCorp from $10.00 to $8.00. They now have an “overweight” rating on the stock.

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.